Literature DB >> 16148091

Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenance.

Sachiko Seo1, Takashi Asai, Toshiki Saito, Takahiro Suzuki, Yasuyuki Morishita, Tetsuya Nakamoto, Motoshi Ichikawa, Go Yamamoto, Masahito Kawazu, Tetsuya Yamagata, Ryuichi Sakai, Kinuko Mitani, Seishi Ogawa, Mineo Kurokawa, Shigeru Chiba, Hisamaru Hirai.   

Abstract

The lymphocyte-specific Cas family protein Cas-L (Crk-associated substrate lymphocyte type) has been implicated to function in lymphocyte movement, mediated mainly by integrin signaling. However, its physiological role is poorly understood. In this study we analyzed the function of Cas-L in lymphocytes using gene-targeted mice. The mutant mice showed a deficit of marginal zone B (MZB) cells and a decrease of cell number in secondary lymphoid organs. An insufficient chemotactic response and perturbed cell adhesion were observed in Cas-L-deficient lymphocytes, suggesting that the aberrant localization was responsible for the deficit of MZB cells. Moreover, we found that lymphocyte trafficking was altered in Cas-L-deficient mice, which gave a potential reason for contraction of secondary lymphoid tissues. Thus, Cas-L affects homeostasis of MZB cells and peripheral lymphoid organs, which is considered to be relevant to impaired lymphocyte migration and adhesion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148091     DOI: 10.4049/jimmunol.175.6.3492

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  SHEP1 partners with CasL to promote marginal zone B-cell maturation.

Authors:  Cecille D Browne; Melanie M Hoefer; Suresh K Chintalapati; Matthew H Cato; Yann Wallez; Derek V Ostertag; Elena B Pasquale; Robert C Rickert
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

2.  The actin-bundling protein L-plastin is essential for marginal zone B cell development.

Authors:  Elizabeth M Todd; Lauren E Deady; Sharon Celeste Morley
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

3.  The transcription factor Pax5 regulates its target genes by recruiting chromatin-modifying proteins in committed B cells.

Authors:  Shane McManus; Anja Ebert; Giorgia Salvagiotto; Jasna Medvedovic; Qiong Sun; Ido Tamir; Markus Jaritz; Hiromi Tagoh; Meinrad Busslinger
Journal:  EMBO J       Date:  2011-05-06       Impact factor: 11.598

Review 4.  Cytoskeletal control of B cell responses to antigens.

Authors:  Pavel Tolar
Journal:  Nat Rev Immunol       Date:  2017-07-10       Impact factor: 53.106

Review 5.  Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases.

Authors:  Elena Shagisultanova; Anna V Gaponova; Rashid Gabbasov; Emmanuelle Nicolas; Erica A Golemis
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

6.  Nedd9 restrains renal cystogenesis in Pkd1-/- mice.

Authors:  Anna S Nikonova; Olga V Plotnikova; Victoria Serzhanova; Andrey Efimov; Igor Bogush; Kathy Q Cai; Harvey H Hensley; Brian L Egleston; Andres Klein-Szanto; Tamina Seeger-Nukpezah; Erica A Golemis
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-19       Impact factor: 11.205

Review 7.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

Review 8.  CAS proteins in health and disease: an update.

Authors:  Anna S Nikonova; Anna V Gaponova; Alexander E Kudinov; Erica A Golemis
Journal:  IUBMB Life       Date:  2014-06-24       Impact factor: 3.885

9.  A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice.

Authors:  J L Little; V Serzhanova; E Izumchenko; B L Egleston; E Parise; A J Klein-Szanto; G Loudon; M Shubina; S Seo; M Kurokawa; M F Ochs; E A Golemis
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

10.  Overexpression and cytoplasmic accumulation of Hepl is associated with clinicopathological parameters and poor prognosis in non-small cell lung cancer.

Authors:  Yuan Miao; Liang Wang; Yang Liu; Ai-Lin Li; Shu-Li Liu; Hong-Yi Cao; Xiu-Peng Zhang; Gui-Yang Jiang; Di Liu; En-Hua Wang
Journal:  Tumour Biol       Date:  2012-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.